Polyarteritis Nodosa

1. Comprehensive Introduction & Overview

Polyarteritis Nodosa (PAN) is a rare, systemic, necrotizing vasculitis that primarily affects medium-sized muscular arteries. Unlike many other forms of vasculitis, PAN is characterized by its predilection for the arterial bifurcations and its notable sparing of the pulmonary circulation. The disease manifests as an inflammatory process that leads to the destruction of the arterial wall, potentially resulting in aneurysm formation, thrombosis, ischemia, or infarction of the tissues supplied by the affected vessels.

Because PAN is a multi-systemic disorder, its clinical presentation is heterogenous, often mimicking other autoimmune, infectious, or malignant conditions. Historically, PAN was often associated with Hepatitis B virus (HBV) infection; however, in the modern clinical landscape, the majority of cases in developed nations are idiopathic.

The name "Polyarteritis Nodosa" is derived from the characteristic inflammatory nodules that form along the small and medium-sized arteries. While the disease can manifest in any organ system, the most commonly affected areas include the kidneys, gastrointestinal tract, peripheral nerves, and skin.

2. Deep-Dive: Etiology and Pathophysiology

Etiological Factors

The etiology of PAN remains largely enigmatic, though current consensus categorizes it into two primary forms:
* HBV-Associated PAN: Occurs in approximately 10–30% of cases. It is driven by the formation of immune complexes (HBsAg-anti-HBs) that deposit in arterial walls, triggering a Type III hypersensitivity reaction.
* Idiopathic (Non-HBV) PAN: The vast majority of cases. While the exact trigger is unknown, it is hypothesized to involve a breakdown in immune tolerance, potentially triggered by occult viral or bacterial antigens.

Pathophysiological Mechanisms

The hallmark of PAN is segmental, necrotizing inflammation. The pathophysiology follows a distinct sequence:
1. Immune Complex Deposition: Circulating immune complexes localize in the tunica media and adventitia of medium-sized arteries.
2. Inflammatory Cascade: Complement activation and recruitment of neutrophils and macrophages occur.
3. Fibrinoid Necrosis: The inflammatory infiltrate invades the vessel wall, leading to the breakdown of internal elastic laminae.
4. Structural Compromise: The weakening of the vessel wall leads to the formation of microaneurysms (the "nodosa" characteristic).
5. Luminal Obstruction: Proliferation of the intima and subsequent thrombosis leads to downstream ischemia and infarction.

3. Clinical Indications & Standard Presentation

PAN is a "great imitator." Patients often present with non-specific systemic symptoms before organ-specific damage becomes apparent.

Early Warning Signs

• Constitutional: Unexplained fever, profound weight loss, fatigue, and night sweats.
• Musculoskeletal: Myalgias, arthralgias, and muscle weakness.

Systemic/Organ-Specific Manifestations

• Dermatological (Common): Livedo reticularis (a lace-like purple discoloration), subcutaneous nodules, palpable purpura, and digital gangrene.
• Renal: Hypertension (due to renal artery involvement/renin activation), hematuria, and proteinuria. Note: Glomerulonephritis is typically absent in pure PAN.
• Neurological: Mononeuritis multiplex (painful, asymmetric sensory and motor nerve deficits) is a classic finding.
• Gastrointestinal: Post-prandial abdominal pain (intestinal angina), cholecystitis, or bowel perforation due to mesenteric ischemia.

Clinical Staging/Grading (The Five-Factor Score - FFS)

The FFS is the gold standard for predicting mortality in PAN patients. A score of ≥1 indicates a worse prognosis.

4. Key Diagnostic Tests and Differential Diagnosis

Diagnostic Gold Standards

1. Angiography: The primary imaging modality. The presence of microaneurysms in the renal, hepatic, or mesenteric arteries is diagnostic of PAN.
2. Tissue Biopsy: If angiography is inconclusive or unavailable, biopsy of an affected organ (e.g., skin, nerve, or muscle) showing necrotizing arteritis is definitive.
3. Laboratory Assessment:
   • Elevated ESR and CRP (non-specific inflammation).
   • Hepatitis B serology (HBsAg/Anti-HBs).
   • ANCA tests: Patients with classic PAN are typically ANCA-negative. If ANCA is positive, consider Microscopic Polyangiitis (MPA).

Differential Diagnosis

It is critical to distinguish PAN from other vasculitides:
* Microscopic Polyangiitis (MPA): Affects smaller vessels (capillaries) and is usually ANCA-positive.
* Granulomatosis with Polyangiitis (GPA): Involves the upper/lower respiratory tract and is usually PR3-ANCA positive.
* Cryoglobulinemic Vasculitis: Associated with Hepatitis C and low complement levels (C4).
* Systemic Lupus Erythematosus (SLE): Usually presents with ANA positivity and multi-organ involvement including joints and skin.

5. Risks, Side Effects, and Contraindications

Therapeutic Management

Treatment depends on the severity and the FFS score:
* Mild/Moderate PAN: Corticosteroids (Prednisone) are the first-line therapy.
* Severe/Organ-Threatening PAN: Combination therapy with high-dose corticosteroids and Cyclophosphamide.
* HBV-Associated PAN: Short-term corticosteroids combined with antiviral therapy (e.g., Lamivudine, Entecavir) and plasma exchange.

Risks and Side Effects of Treatment

• Corticosteroids: Osteoporosis, hyperglycemia, hypertension, mood disturbances, and increased risk of opportunistic infections.
• Cyclophosphamide: Hemorrhagic cystitis, bladder cancer (long-term risk), myelosuppression, and infertility (gonadotoxicity).
• Biologics (Rituximab/Infliximab): Infusion reactions, reactivation of latent infections (e.g., TB or Hep B).

6. FAQ: Frequently Asked Questions

1. Is Polyarteritis Nodosa a fatal disease?
Without treatment, the prognosis is poor, with high mortality rates. However, with modern immunosuppressive therapy, the 5-year survival rate is approximately 80–90%.

2. Is PAN contagious?
No. PAN is an autoimmune condition. While Hepatitis B can trigger it, the vasculitis itself cannot be passed from person to person.

3. Why is the lung spared in PAN?
The pathophysiology of PAN involves medium-sized arteries. Because the pulmonary circulation is largely composed of smaller vessels and capillaries, it is typically unaffected, unlike in GPA or MPA.

4. Can PAN be cured?
"Cure" is a difficult term in autoimmune disease. Patients can achieve long-term remission, but the risk of relapse exists, necessitating periodic monitoring.

5. What is the role of the biopsy in diagnosis?
Biopsy provides histopathological confirmation of necrotizing arteritis, which is the defining feature of the disease.

6. Does PAN affect children?
Yes, there is a pediatric form known as Cutaneous Polyarteritis Nodosa, which is usually less severe and primarily involves the skin.

7. Is there a specific diet for PAN patients?
While no specific diet cures PAN, a heart-healthy, low-sodium diet is recommended to manage steroid-induced hypertension and fluid retention.

8. Can I get pregnant while having PAN?
Pregnancy is high-risk for patients with PAN. It should only be considered during stable remission and under the strict supervision of a rheumatologist and high-risk obstetrician.

9. How is Mononeuritis Multiplex linked to PAN?
The vasa nervorum (small arteries supplying nerves) become inflamed and occluded, causing sudden, painful nerve death in specific patterns.

10. What is the most common cause of death in PAN?
Historically, it was renal failure or gastrointestinal perforation. Today, with better management, treatment-related complications (infections) are a significant concern.

7. Long-term Prognosis and Clinical Outlook

The prognosis for patients with Polyarteritis Nodosa is heavily dependent on early diagnosis and the extent of organ involvement at the time of presentation.

Long-term Care Strategy

• Regular Monitoring: Periodic blood pressure monitoring, urinalysis for proteinuria, and inflammatory marker assessment (ESR/CRP).
• Maintenance Therapy: Once remission is achieved with induction therapy, patients are often tapered to lower doses of immunosuppressants or transitioned to steroid-sparing agents (e.g., Azathioprine or Methotrexate).
• Complication Management: Aggressive management of hypertension is vital to preventing secondary renal decline, as renal ischemia is a primary driver of morbidity.

Conclusion

Polyarteritis Nodosa represents a complex, systemic challenge requiring a multi-disciplinary approach involving rheumatologists, nephrologists, neurologists, and dermatologists. While the disease can be devastating, the shift toward standardized treatment protocols—specifically the use of the Five-Factor Score and aggressive immunosuppression—has transformed PAN from a near-certain terminal diagnosis into a manageable chronic condition. Clinicians must maintain a high index of suspicion for patients presenting with unexplained constitutional symptoms, persistent hypertension, or sudden onset neuropathy.

Medical Disclaimer: This guide is for educational purposes only and does not constitute formal medical advice. Diagnosis and treatment of Polyarteritis Nodosa must be managed by a qualified medical professional. Always consult with a board-certified rheumatologist for clinical decision-making.